R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012.
DOI : 10.3322/caac.20138

D. Keizman, N. Maimon, and M. Gottfried, Metastatic Hormone Refractory Prostate Cancer, American Journal of Clinical Oncology, vol.37, issue.3, 2012.
DOI : 10.1097/COC.0b013e318248dc1e

A. Godoy, I. Chung, V. Montecinos, R. Buttyan, C. Johnson et al., Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate, AJP: Endocrinology and Metabolism, vol.304, issue.11, pp.1131-1139, 2013.
DOI : 10.1152/ajpendo.00602.2012

G. Russo, M. Mischi, W. Scheepens, J. De-la-rosette, and H. Wijkstra, Angiogenesis in prostate cancer: onset, progression and imaging, BJU International, vol.45, issue.11c, pp.794-808, 2012.
DOI : 10.1111/j.1464-410X.2012.11444.x

E. Antonarakis and M. Carducci, Targeting angiogenesis for the treatment of prostate cancer, Expert Opinion on Therapeutic Targets, vol.29, issue.21, pp.365-376
DOI : 10.1200/JCO.2007.12.4487

J. Blanc, R. Geney, and C. Menet, Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design, Anti-Cancer Agents in Medicinal Chemistry, vol.13, issue.5, pp.731-747, 2013.
DOI : 10.2174/1871520611313050008

P. Baluk, H. Hashizume, and D. Mcdonald, Cellular abnormalities of blood vessels as targets in cancer, Current Opinion in Genetics & Development, vol.15, issue.1, pp.102-111, 2005.
DOI : 10.1016/j.gde.2004.12.005

K. Hida, Y. Hida, and M. Shindoh, Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies, Cancer Science, vol.156, issue.3, pp.459-466, 2008.
DOI : 10.1101/gad.436307
URL : http://doi.org/10.1111/j.1349-7006.2007.00704.x

K. Hida, Y. Hida, D. Amin, A. Flint, D. Panigrahy et al., Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities, Cancer Research, vol.64, issue.22, pp.8249-8255, 2004.
DOI : 10.1158/0008-5472.CAN-04-1567
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.585.1563

B. Bussolati, I. Deambrosis, S. Russo, M. Deregibus, and G. Camussi, Altered angiogenesis and survival in human tumor-derived endothelial cells, The FASEB Journal, vol.17, pp.1159-1161, 2003.
DOI : 10.1096/fj.02-0557fje

J. Van-beijnum, R. Dings, E. Van-der-linden, B. Zwaans, F. Ramaekers et al., Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature, Blood, vol.108, issue.7, pp.2339-2348, 2006.
DOI : 10.1182/blood-2006-02-004291

A. Dudley and M. Klangsbrun, Tumor endothelial cells have features of adult stem cells, Cell Cycle, vol.8, issue.2, pp.236-238, 2009.
DOI : 10.4161/cc.8.2.7413

B. Bussolati, C. Grange, and G. Camussi, Tumor exploits alternative strategies to achieve vascularization, The FASEB Journal, vol.25, issue.9, pp.2874-2882, 2001.
DOI : 10.1096/fj.10-180323

B. Bussolati, C. Grange, S. Bruno, S. Buttiglieri, M. Deregibus et al., Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures, Experimental Cell Research, vol.312, issue.6, pp.913-924, 2006.
DOI : 10.1016/j.yexcr.2005.12.004

V. Fonsato, S. Buttiglieri, M. Deregibus, V. Puntorieri, B. Bussolati et al., Expression of Pax2 in Human Renal Tumor-Derived Endothelial Cells Sustains Apoptosis Resistance and Angiogenesis, The American Journal of Pathology, vol.168, issue.2, pp.706-713, 2006.
DOI : 10.2353/ajpath.2006.050776

Y. Xiong, H. Sun, W. Zhang, X. Zhu, P. Zhuang et al., Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells, Clinical Cancer Research, vol.15, issue.15, pp.4838-4846, 2009.
DOI : 10.1158/1078-0432.CCR-08-2780

A. Dudley, Z. Khan, S. Shih, S. Kang, B. Zwaans et al., Calcification of Multipotent Prostate Tumor Endothelium, Cancer Cell, vol.14, issue.3, pp.201-211, 2008.
DOI : 10.1016/j.ccr.2008.06.017

C. Grange, B. Bussolati, S. Bruno, V. Fonsato, A. Sapino et al., Isolation and characterization of human breast tumor-derived endothelial cells, Oncology Reports, vol.15, pp.381-386, 2006.
DOI : 10.3892/or.15.2.381

M. Deregibus, V. Cantaluppi, R. Calogero, L. Iacono, M. Tetta et al., Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA, Blood, vol.110, issue.7, pp.2440-2448, 2007.
DOI : 10.1182/blood-2007-03-078709

G. Bidaux, M. Flourakis, S. Thebault, A. Zholos, B. Beck et al., Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function, Journal of Clinical Investigation, vol.117, issue.6, pp.1647-1657, 2007.
DOI : 10.1172/JCI30168DS1
URL : https://hal.archives-ouvertes.fr/inserm-00137718

F. Pla, A. Maric, D. Brazer, S. Giacobini, P. Liu et al., Canonical Transient Receptor Potential 1 Plays a Role in Basic Fibroblast Growth Factor (bFGF)/FGF Receptor-1-Induced Ca2+ Entry and Embryonic Rat Neural Stem Cell Proliferation, Journal of Neuroscience, vol.25, issue.10, pp.2687-2701, 2005.
DOI : 10.1523/JNEUROSCI.0951-04.2005

M. Zaborowska, S. Szmit, and C. Szczylik, Sorafenib in progressive castrateresistant prostate cancer. can we talk about a new therapeutic option, Arch Med Sci, vol.8, pp.528-532, 2012.

G. Sonpavde, P. Periman, D. Bernold, D. Weckstein, M. Fleming et al., Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy, Annals of Oncology, vol.21, issue.2, pp.319-324, 2010.
DOI : 10.1093/annonc/mdp323
URL : http://annonc.oxfordjournals.org/cgi/content/short/21/2/319

D. Castellano, J. González-larriba, L. Antón-aparicio, J. Cassinello, E. Grande et al., Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients, Expert Opinion on Pharmacotherapy, vol.5, issue.20, pp.2433-2439, 2011.
DOI : 10.1016/j.ejca.2009.02.011

T. Matsumoto, S. Bohman, J. Dixelius, T. Berge, A. Dimberg et al., VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis, The EMBO Journal, vol.277, issue.13, pp.2342-2353, 2005.
DOI : 10.1038/sj.emboj.7600709

A. Godoy, A. Watts, P. Sotomayor, V. Montecinos, W. Huss et al., Androgen Receptor Is Causally Involved in the Homeostasis of the Human Prostate Endothelial Cell, Endocrinology, vol.149, issue.6, pp.2959-2969, 2008.
DOI : 10.1210/en.2007-1078

S. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, vol.64, pp.43-90067099, 2004.

M. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin et al., IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, issue.8, pp.2538-2548, 2011.
DOI : 10.1158/1078-0432.CCR-10-3314

P. Kharaziha, P. Rodriguez, Q. Li, H. Rundqvist, A. Björklund et al., Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells, Cell Death and Disease, vol.22, issue.1, p.262, 2012.
DOI : 10.1038/cddis.2012.1

A. Grover, M. Tangrea, K. Woodson, B. Wallis, J. Hanson et al., Tumor-associated endothelial cells display GSTP1 and RAR beta2 promoter methylation in human prostate cancer, Journal of Translational Medicine, vol.4, issue.1, p.13, 2006.
DOI : 10.1186/1479-5876-4-13

W. Luo, Q. Hu, D. Wang, K. Deeb, Y. Ma et al., Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue, Oncotarget, vol.4, issue.9, pp.1472-1483, 2013.
DOI : 10.18632/oncotarget.1269

J. Martínez-jabaloyas, J. March-villalba, M. Navarro-garcía, and F. Dasi, Anti-angiogenic therapies in prostate cancer, Expert Opinion on Biological Therapy, vol.361836, issue.1, pp.1-5, 2013.
DOI : 10.1016/j.leukres.2010.07.038

D. Michaelson, M. Oudard, S. Ou, Y. Sengeløv, L. Saad et al., Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer, J ClinOncol, vol.2014, issue.322, pp.76-82

S. Steinbild, K. Mross, A. Frost, R. Morant, S. Gillessen et al., A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV, British Journal of Cancer, vol.14, issue.11, pp.1480-1527, 2007.
DOI : 10.1158/0008-5472.CAN-04-1443

F. Pla, Page 12 of 13 http://www.biomedcentral.com/1471-2407/14/939 A Phase II clinical trial of sorafenib in androgen-independent prostate cancer, BMC Cancer Clin Cancer Res, vol.14, issue.14, pp.939209-214, 2008.

J. Aragon-ching, L. Jain, J. Gulley, P. Arlen, J. Wright et al., Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer, BJU International, vol.16, issue.12, pp.1636-1640, 2009.
DOI : 10.1111/j.1464-410X.2008.08327.x

D. Michaelson, M. Regan, M. Oh, W. Kaufman, D. Olivier et al., Phase II study of sunitinib in men withadvanced prostate cancer, pp.913-920, 2009.

E. Dib, M. Maia, S. Lima-ade, E. De-paula-fiod-costa, M. De-moraes-filho et al., Angiogenic Inhibition of Sunitinib Malate, Current Eye Research, vol.70, issue.7, pp.567-574, 2012.
DOI : 10.1167/iovs.05-0772

M. Nilsson, P. Zage, L. Zeng, L. Xu, T. Cascone et al., Multiple receptor tyrosine kinases regulate HIF-1?? and HIF-2?? in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors, Oncogene, vol.60, issue.20, pp.2938-2949, 2010.
DOI : 10.1007/s11060-005-3279-0

T. Bayyoud, J. Hofmann, M. Spitzer, K. Bartz-schmidt, and E. Yoeruek, Cytotoxic Properties of Sunitinib and Sorafenib on Human Corneal Epithelial Cells, Current Eye Research, vol.45, issue.2, pp.149-154, 2013.
DOI : 10.1097/ICO.0b013e31823f8b9c

B. Bussolati, B. Assenzio, M. Deregibus, and G. Camussi, The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway, Journal of Molecular Medicine, vol.63, issue.10, pp.852-863, 2006.
DOI : 10.1007/s00109-006-0075-z

E. Beardsley, S. Hotte, S. North, S. Ellard, E. Winquist et al., A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer, Investigational New Drugs, vol.375, issue.1, pp.1652-1659, 2012.
DOI : 10.1007/s10637-011-9722-5